DLK2

Across TCGA pan-cancer cohorts, DLK2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of DLK2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where DLK2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DLK2 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

KIRC, THCA, and LIHC are the cancer types where DLK2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DLK2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	II,III,IV	+1.118	<.001	12	view →
THCA	Male	III,IV	−0.702	<.001	11	view →
LIHC	Male	II,III,IV	+1.013	<.001	9	view →
LUSC	Female	II,III,IV	+2.821	<.001	8	view →
BRCA	Female	II,III,IV	−1.525	<.001	8	view →
COAD	Male	II,III,IV	+0.771	<.001	8	view →
CHOL	Male	All	+1.120	<.001	5	view →
LUAD	All	II,III,IV	+0.491	.011	5	view →
KICH	Female	All	−0.385	.001	3	view →
PRAD	All	All	−1.222	<.001	2	view →
HNSC	Male	All	+0.672	.027	2	view →
STAD	All	IV	+0.606	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

DLK2–KIRC

Open the KIRC breakdown →